The BCG Vaccine is a vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.
From the plagues of medieval Europe to the influenza pandemic of 1918, the specter of the next public health disaster has gripped the minds of scientists, captivated the imaginations of writers and vexed conspiracy theorists.
All over the world, except in China, the place where it all began, the COVID-19 pandemic is making its relentless way through the population. So far, it has caused nearly 34,000 deaths – and the situation in the US is still worsening with over 142,000 cases and 2,489 deaths. In Australia, the number of cases has climbed to 4,093, with 16 fatalities.
Professor Kathryn North AC, Director of the Murdoch Children's Research Institute in Melbourne, Australia, has announced its infectious disease researchers are preparing to roll-out a multi-center randomized controlled clinical trial of the BCG vaccine against COVID-19.
The coronavirus disease (COVID-19) had taken a toll on the world, affecting 168 countries and more than 417,000 people. So far, more than 18,600 people have died due to complications of the disease. Scientists across the globe race to develop the first vaccine against the novel coronavirus.
In September 2018, the National Institute of Allergy and Infectious Diseases, part of the NIH, issued its Strategic Plan for Tuberculosis Research, which outlined research priorities to reduce and ultimately end the burden of tuberculosis.
Each year, more than 100 million newborns around the world receive vaccinations against Mycobacterium tuberculosis, or TB, which infects about one-quarter of the world's population.
A new primate study published in the journal Nature in January 2020, reports that the almost century-old BCG vaccine against tuberculosis, may be used differently to achieve better protection against lung tuberculosis. While more work remains to be carried out before the findings can be accepted as the basis for clinical practice, they are extremely promising in the fight against this killer.
Researchers have found that the BCG vaccine is more efficacious in the prevention of TB when administered intravenously.
Worldwide, more people die from tuberculosis than any other infectious disease, even though the vast majority were vaccinated.
A new study published in the journal Scientific Reports says that for the first time a vaccine has been created against bovine tuberculosis that can be given without affecting the ability to diagnose tuberculosis later using the PPD skin test.
Seattle Children's Research Institute is one of three recipients of $30 million in first-year-funding provided by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to establish centers for immunology research to accelerate progress in tuberculosis vaccine development.
A team of researchers in the Department of Microbiology, Immunology and Pathology at Colorado State University aim to advance what is known about the complex immune response necessary to prevent tuberculosis disease.
The San Antonio Medical Foundation has awarded Texas Biomedical Research Institute Professor Jordi B. Torrelles, Ph.D., with a $173,000 grant to study a modified Mycobacterium bovis Bacillus Calmette et Guérin (BCG) vaccine shown to have promise for treating bladder cancer.
A new study published on October 29, 2019, in the New England Journal of Medicine, reports a new vaccine which could change the face of tuberculosis prevention. The disease kills 1.5 million people worldwide each year.
A common tuberculosis vaccine could decrease the risk of lung cancer if administered during early childhood, according to a study published Sept. 25 in JAMA Network Online.
Scientists working on a new tuberculosis vaccine have achieved a major step forward by showing that a promising TB antigen and a novel vaccine adjuvant can be protected from heat damage with a technique developed at the University of Bath.
For years, scientists have been trying to come up with a better way to protect people against tuberculosis, the disease caused by infection with the Mycobacterium tuberculosis bacteria.
Vaccinations have begun in a Phase 1 human clinical trial testing a freeze-dried, temperature-stable formulation of an experimental tuberculosis vaccine candidate.
GlaxoSmithKline has come up with an experimental vaccine against tuberculosis (TB) that has shown effective prevention of the infection in half of the population it has been administered to. This could be a breakthrough in preventing the killer disease say researchers since most of the recent vaccines developed against the disease have failed to show efficacy.
Aeras, a nonprofit organization dedicated to developing vaccines against tuberculosis (TB), today announced the publication of the full results from a Phase 2, randomized, controlled clinical trial of two TB vaccines-- the currently available BCG vaccine and an investigational vaccine, H4:IC31--in the New England Journal of Medicine (NEJM).